Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 402,083,872
  • Shares Outstanding, K 2,406,679
  • Annual Sales, $ 85,159 M
  • Annual Income, $ 35,153 M
  • 60-Month Beta 0.53
  • Price/Sales 4.72
  • Price/Cash Flow 12.11
  • Price/Book 5.57
Trade JNJ with:

Options Overview Details

View History
  • Implied Volatility 18.52% ( +0.61%)
  • Historical Volatility 11.04%
  • IV Percentile 83%
  • IV Rank 60.20%
  • IV High 22.48% on 08/05/24
  • IV Low 12.53% on 05/09/24
  • Put/Call Vol Ratio 0.63
  • Today's Volume 13,948
  • Volume Avg (30-Day) 23,779
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 399,795
  • Open Int (30-Day) 376,845

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 2.19
  • Number of Estimates 7
  • High Estimate 2.35
  • Low Estimate 2.02
  • Prior Year 2.66
  • Growth Rate Est. (year over year) -17.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
159.13 +4.53%
on 08/19/24
168.85 -1.49%
on 09/04/24
+6.95 (+4.36%)
since 08/16/24
3-Month
144.50 +15.11%
on 07/05/24
168.85 -1.49%
on 09/04/24
+20.69 (+14.20%)
since 06/18/24
52-Week
143.13 +16.21%
on 04/18/24
168.85 -1.49%
on 09/04/24
+3.87 (+2.38%)
since 09/18/23

Most Recent Stories

More News
ISRG Stock Rallies 14% in 3 Months: Is It Still Worth Buying?

Shares of Intuitive Surgical ISRG have risen 14.2% in the past three months, outperforming the Zacks Medical - Instruments industry’s growth of 3.8% and the broader Zacks Medical sector’s return of...

JNJ : 166.87 (-0.12%)
MDT : 88.10 (-0.60%)
ISRG : 482.27 (-0.22%)
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?

Teva Pharmaceutical Industries Limited’s TEVA stock has risen 72.5% so far this year compared with an increase of 17.9% for the industry. The stock has also outperformed the sector and the S&P 500, as...

SNY : 57.26 (+0.62%)
JNJ : 166.87 (-0.12%)
TEVA : 17.79 (-0.34%)
ABBV : 194.09 (+0.33%)
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More

This week, the FDA approved J&J’s JNJ Tremfya for treating an inflammatory bowel disease condition (“IBD”), ulcerative colitis. Novo Nordisk’s NVO oral obesity pill, amycretin, showed faster weight...

REGN : 1,144.14 (-0.23%)
SNY : 57.26 (+0.62%)
JNJ : 166.87 (-0.12%)
NVO : 132.76 (+0.58%)
Should You Buy Novavax Stock After This Regulatory Win?

The biotech continues to earn important wins, but is it enough?

MRNA : 70.40 (-2.21%)
BNTX : 116.58 (-6.52%)
JNJ : 166.87 (-0.12%)
PFE : 29.80 (-0.10%)
NVAX : 12.70 (-1.78%)
SNY : 57.26 (+0.62%)
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis

Johnson & Johnson JNJ announced that the FDA approved its blockbuster immunology medicine, Tremfya (guselkumab), for a third indication. The drug is approved to treat adults with moderately to severely...

JNJ : 166.87 (-0.12%)
LLY : 908.55 (+0.26%)
ABBV : 194.09 (+0.33%)
Is Hims & Hers Health the Next Teladoc?

Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic.

PFE : 29.80 (-0.10%)
JNJ : 166.87 (-0.12%)
TGT : 154.71 (+1.81%)
NVO : 132.76 (+0.58%)
LLY : 908.55 (+0.26%)
TDOC : 9.24 (+1.43%)
MRNA : 70.40 (-2.21%)
HIMS : 16.35 (+1.55%)
2 Stocks That Are Passive Income Machines to Buy and Hold Forever

You can take these dividends straight to the bank.

ABT : 115.45 (-2.27%)
JNJ : 166.87 (-0.12%)
Is Johnson & Johnson Underperforming the S&P 500?

Johnson & Johnson has underperformed the S&P 500 recently, but analysts are moderately optimistic about the stock’s potential.

JNJ : 166.87 (-0.12%)
$SPX : 5,661.39 (+0.48%)
LLY : 908.55 (+0.26%)
2 Dividend Stocks With Payouts That May Not Be as Safe as They Seem

Johnson & Johnson and Altria Group are two prominent dividend stocks, but I wouldn't rely on their payouts.

INTC : 20.78 (-3.21%)
WBA : 9.10 (+0.44%)
JNJ : 166.87 (-0.12%)
MO : 50.71 (+0.42%)
J&J Inches Closer to Talc Lawsuit Resolution with $1.1 Billion Payout Increase

Johnson & Johnson (JNJ) has increased its talc settlement offer by an additional $1.1 billion, bringing the total settlement to over $9 billion. This new offer comes as J&J seeks to resolve claims that...

JNJ : 166.87 (-0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 169.67
2nd Resistance Point 168.70
1st Resistance Point 167.88
Last Price 166.87
1st Support Level 166.09
2nd Support Level 165.12
3rd Support Level 164.30

See More

52-Week High 168.85
Last Price 166.87
Fibonacci 61.8% 159.02
Fibonacci 50% 155.99
Fibonacci 38.2% 152.96
52-Week Low 143.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar